Biotech Values

[DewDiligence]

>If approved, does Sandoz launch "at risk"? I would vote for yes.<

Make that two votes for Yes. I think this has been NVS’ game plan from day one.

>Good news is there's a second product to value and the analysts that had "everything ex-lovenox" at a dollar or what not will need to rethink.<

Correct! Moreover, we now know that MNTA/NVS have first-to-file status on Copaxone.



Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”